191 related articles for article (PubMed ID: 28324247)
1. Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
Lin WZ; Xu QN; Wang HB; Li XY
Breast Cancer; 2017 May; 24(3):345-352. PubMed ID: 28324247
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials.
Chanchan G; Xiangyu S; Fangfang S; Yan C; Xiaoyi G
PLoS One; 2018; 13(9):e0204202. PubMed ID: 30235292
[TBL] [Abstract][Full Text] [Related]
4. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
[TBL] [Abstract][Full Text] [Related]
5. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Niraula S; Ocana A
Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer.
Hua YM
Arch Gynecol Obstet; 2019 Nov; 300(5):1377-1382. PubMed ID: 31599350
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Li M; Xiong Y; Liao C; He Y; Duan S; Yi F; Wei Y; Zhang W
Breast Cancer Res Treat; 2020 Apr; 180(2):269-278. PubMed ID: 32008124
[TBL] [Abstract][Full Text] [Related]
9. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Telford C; Jones N; Livings C; Batson S
Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
[TBL] [Abstract][Full Text] [Related]
10. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.
Xu L; Yan N; Li Z; Luo L; Wu X; Liu Q; Xu Y; Cao Y
Onco Targets Ther; 2018; 11():8389-8398. PubMed ID: 30568462
[TBL] [Abstract][Full Text] [Related]
11. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Tan PS; Haaland B; Montero AJ; Lopes G
Breast Cancer Res Treat; 2013 Apr; 138(3):961-5. PubMed ID: 23542955
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
[TBL] [Abstract][Full Text] [Related]
14. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
Cope S; Ouwens MJ; Jansen JP; Schmid P
Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Gong DD; Man CF; Xu J; Fan Y
Asian Pac J Cancer Prev; 2014; 15(5):2095-100. PubMed ID: 24716940
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.
Graham J; Pitz M; Gordon V; Grenier D; Amir E; Niraula S
Cancer Treat Rev; 2016 Apr; 45():1-6. PubMed ID: 26922660
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
Raphael J; Desautels D; Pritchard KI; Petkova E; Shah PS
Eur J Cancer; 2018 Mar; 91():38-46. PubMed ID: 29331750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
